Abstract Eslicarbazepine acetate (Aptiom®, Zebinix®) is approved for the adjunctive
treatment of partial-onset seizures in adults aged≥ 18 years. Adjunctive therapy with oral …

Eslicarbazepine acetate (Aptiom®) is a once-daily, orally administered antiepileptic drug
(AED) approved previously in the EU, USA and several other countries for use as adjunctive …

Eslicarbazepine acetate is a is a once-daily antiepileptic drug (AED) that was approved in
2009 by the European Medicines Agency (EMA)(Zebinix™), and in 2013 by the US Food …

Objective: To explore the efficacy and safety of eslicarbazepine acetate (BIA 2‐093), a new
antiepileptic drug, as adjunctive therapy in adult patients with partial epilepsy. Methods: A …

Objectives–To evaluate the efficacy and safety of eslicarbazepine acetate (ESL) as
adjunctive therapy in adults with partial‐onset seizures. Material and methods–Double …

Objective To evaluate the efficacy and safety of adjunctive eslicarbazepine acetate (ESL) in
patients with refractory partial‐onset seizures. Methods This randomized, placebo …

Purpose: To study the efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive
therapy for refractory partial seizures in adults with≥ 4 partial‐onset seizures (simple or …

Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug that is approved as
adjunctive therapy in adults with focal-onset seizures. Following oral administration, ESL is …

Objective To assess the effectiveness and tolerability of eslicarbazepine acetate (ESL)
monotherapy in routine clinical practice for the treatment of focal‐onset seizures. Methods …

Objective To assess seizure control and tolerability of eslicarbazepine acetate (ESL) as
adjunctive therapy to one baseline antiepileptic drug (AED), in adults with partial‐onset …